PND18 Impact of Co-Morbidities on the Economic Burden of Parkinson'S Disease in Germany Post-2000  by Takyar, S. et al.
time horizon and resources usage from a previous cost-effectiveness study for
medications used to treat hepatic encephalopathy from the Mexican Institute of
Social Security (IMSS) perspective and to complement it with a budget impact
analysis. METHODS: CE analysis of treatments used for acute HE, based in a deci-
sion tree model, and considering a horizon of 10 days. Alternatives available at the
IMSS are: lactulose, L-ornithine L-aspartate (LOLA), neomycin and alpha (a)poly-
morph rifaximin (the new alternative). Percentage of patients with improvement in
signs and symptoms of HE was the effectiveness measure and s based on available
published studies(Huang 2007 and Qian 2009). Only direct medical costs were con-
sidered and obtained from IMSS. Univariated sensitivity analysis, using pricing
discounts and effectiveness were performed and budget impact simulations were
developed. RESULTS: LOLA US$4024, lactulose US$4032, neomycin US$4060 and
rifaximin US $4039 final costs. In relation to effectiveness, the percentage of pa-
tients who presented improved signs and symptoms for each alternative is as
follows: lactulose and LOLA 55%, neomycin 64% and rifixamin 90%. Cost effective-
ness ratios are: lactulose US$7331, LOLA $7316, neomycin US$6344 and rifixamin
US$4488. The incremental cost effectiveness analysis indicates that LOLA and neo-
mycin are surpassed by lactulose and rifaximin, which are located on the efficiency
line. For the sensitivity analysis with one hospitalization day reduced due to the
improved efficacy, rifaximin was the dominating alternative. If lactulose and neo-
mycin are substituted by rifaximin in the estimated population(6,194 to 21,680
potential range of patients with HE in the Mexican Health System), the budget
impact shows savings equivalent to 77.74 y 72.36%, respectively. CONCLUSIONS:
Alpha (a) polymorph rifaximin is a highly cost effective alternative for treating
acute HE from an institutional perspective in México.
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OBJECTIVES: To estimate the budgetary impact of RRMS treatment from the per-
spective of the NHS in Spain (valued Euros-2011), in order to determine which
treatment is most efficient from the payer’s perspective.METHODS: IMS sales data
for multiple sclerosis drugs were used to estimate the total number of patients
treated with each of the drugs used during 2011. The number of patients receiving
treatment was calculated from the yearly cost of each treatment per patient (ex-
factory price excluding VAT) because IMS presents total sales expressed as ex-
factory price, which means that the yearly cost of the drug expressed as ex-factory
price must be used to estimate the number of patients from the IMS sales data.
Although there are clear differences in the effectiveness of the treatments used,
these differences do not always explain differences in prices (higher incremental
costs). RESULTS: Total expenditure in Spain in 2011 was €259 million. Among the
patients, 47% were treated with interferon beta-1a, 27% with interferon beta-1b,
16% with glatiramer acetate and 10% with natalizumab. In the unlikely event that
all patients had used interferon beta-1a in Spain, total expenditure would have
been between -10% and 6.3%, depending on the drug used. If interferon beta 1b
had been used by all patients, the total savings in Spain during 2011 would have
been over 12.5%. Nonetheless, the greatest savings (15% of total expenditure)
would have been achieved if all patients had been treated with glatiramer acetate.
CONCLUSIONS: Despite the limitations of the study (only direct drug costs were
considered and the number of patients receiving treatment was extrapolated) this
methodology may aid decision-making by policy makers, especially in times of
economic difficulty, by showing which medication is more efficient.
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OBJECTIVES:BUCCOLAM (oromucosal midazolam) is approved for the treatment of
prolonged, acute, convulsive seizures in children and was the first product to re-
ceive a Paediatric-Use Marketing Authorisation (PUMA) in September 2011. The
product label includes use by parents and other carers such as teachers. Current
care in Germany for first line treatment consists mainly of rectal diazepam with
some use of buccal lorazepam, clonazepam and chloral hydrate. Some non-family
carers can be reluctant to administer these products due to concerns about social
acceptability, dignity or labelling issues. A decision tree model has been developed
to assess the cost of BUCCOLAM compared to current care for prolonged acute
convulsive seizures initially occurring in the community setting. METHODS: The
model evaluates costs along the treatment pathway when a child has a seizure
including whether or not carers administer treatment, whether an ambulance is
required and whether or not patients are taken to hospital and require an inpatient
stay. Data were obtained from a variety of sources including clinical effectiveness
estimates from McIntyre et al. 2005, and a Delphi panel. Costs were taken from
published sources. Estimates of the total eligible population were taken from epi-
lepsy prevalence data and the Delphi panel. RESULTS: Over one year, compared to
the mix of treatments representing current care, BUCCOLAM showed a reduction
in per patient costs of €3,469. Compared to treatment with rectal diazepam alone,
the most commonly used treatment, BUCCOLAM showed a cost reduction of
€3,533. It was expected that36,000 patients would be eligible. At an uptake of 20%
BUCCOLAM would reduce health care expenditure by €19.4 million in the first year.
CONCLUSIONS: Treatment with BUCCOLAM is cost-saving compared to current
care and treatment with rectal diazepam through a reduction in the need for am-
bulance call-outs and hospital stays.
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OBJECTIVES: Epilepsy is one of the most common chronic neurological disorders in
the world; therefore it is associated with substantial use of medical resources in
health institutions. Approximately 60% of patients with epilepsy suffer from par-
tial-onset seizures (POS), and among these, an estimated 30% have refractory dis-
ease. The objective of this study was to analyze the cost-effectiveness of lacos-
amide (LCM), a newer anti-epileptic drug (AED), versus second generation AEDs in
patients with refractory POS. METHODS: We conducted an economic evaluation,
using lamotrigine (LTG) 300 mg/day and topiramate (TPM) 200 mg/day as compar-
ators for LCM 200 and 400 mg/day. The perspective was the Mexican Social Security
Institute, in accordance with Mexican guidelines for Economic Evaluations. The
model included the cost of drug acquisition and management of adverse events
(AE) during the titration and 12 weeks of maintenance. Resource use associated
with AEs was defined according to the information gathered in a Delphi Panel. The
efficacy measure was the50% responder rate; i.e., the percentage of patients who
showed a 50% decrease in seizure frequency from baseline. An indirect compar-
ison was made. RESULTS: The adjusted response rates were 33% for LCM 200
mg/day (34% unadjusted), 39% LCM 400 mg/day (41% unadjusted), 24% for LTG (20%
unadjusted) and 31% for TPM (27% unadjusted). Costs per patient considering the
adjustment was MX$6,872, $7,836, $6,954 and $6,485 for LCM 200 mg, LCM 400 mg,
LTG and TPM, respectively. The cost per responder was lower for LCM 200 and 400
mg/day ($20,825 and $20,093, respectively) than TPM and LTG ($20,918 and $28,974,
respectively). Considering unadjusted data, LCM 200 and 400 mg/day had greater
differential in costs per responder compared with TPM or LTG. CONCLUSIONS:
From a Mexican perspective, lacosamide represents a cost-effective treatment op-
tion for patients with POS. Sponsored by UCB.
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OBJECTIVES: Controlled trials have found therapeutic plasma exchange (TPE) and
intravenous immunoglobulin (IVIg) infusion therapy to be equally efficacious in
treating Guillain-Barré syndrome (GBS). Due to increases in the price of IVIg com-
pared to human serum albumin (HSA), used as a replacement fluid in TPE, direct
hospital-level expenditures for TPE and IVIg for meaningful cost-differences be-
tween these treatments were exemined for Turkey. METHODS: Cost were calcu-
lated with Hacettepe University Hospital procedures for one cycle IVIg and TPE.
One cycle were defined for IVIg and TPE as 5 days and 5 series, respectively. A model
was developed which allows hospitals to input cost and reimbursement amounts
for both IVIg and TPE with HSA that results in real-time valuations of these inter-
ventions. Reimbursement amounts were obtained from publicly available Social
Security Institution (SGK) data resources to determine payment rates for TPE and
IVIg. Only direct cost and payer perspective were used for the calculation.
RESULTS: The direct cost of IVIg infusion sessions totaling 140,0 grams for 5 days
was 18,841 TL compared to a series of five TPE procedures, which had direct costs of
6,529 TL.CONCLUSIONS: In GBS patients, direct costs of IVIg therapy are more than
twice that of TPE. Given equivalent efficacy and similar severity and frequencies of
adverse events, TPE appears to be a less expensive first-line therapy option for
treatment of patients with GBS for Turkey.
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OBJECTIVES: To collate the published evidence evaluating economic burden of
co-morbidities in patients with Parkinson’s disease (PD) in Germany. METHODS: A
systematic search of electronic literature databases (Embase® and MEDLINE®) was
conducted from January 2001 to June 2012 to identify economic studies in English
evaluating co-morbidities in patients with PD in Germany. RESULTS: Four studies
of the 267 citations retrieved met the pre-defined inclusion criteria. During 2000-
2002, direct costs were higher in patients with dyskinesias and/or motor fluctua-
tions (€3300 [€4630]) or dementia (€3110 [€5610]) than patients without motor com-
plications (€1450 [€3760]) or dementia (€1530 [3460]). However, indirect costs were
higher for patients without dementia (€3780 [€6870]) than patients with dementia
(€1080 [€4110]). In 2006, daily total costs and PD drug treatment costs decreased
significantly in patients with dementia (€7.3 [7.3]; p0.05) and depression (€6.6 [5.8];
p0.05) than patients without dementia (€9.3 [13.9]) and depression (€7.6 [6.8]),
respectively. The decrease in the costs observed across patients presenting with
these co-morbidities may be attributed to the inadequate treatment of depression
or dementia among patients with PD. In 2009, direct costs demonstrated a signifi-
cant increase in patients with dyskinesia (€16,544 vs. €11,322; p0.003), dementia
(€21,142 vs. €10,619; p0.001), depression (€15,904 vs. €8826; p0.001), or psychosis
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(€15,398 vs. €8614; p0.016) than patients without these co-morbidities. Indirect
costs were also higher in PD patients with these co-morbidities than patients with
PD alone; the difference being significant only for dementia (€8201 vs. €2964;
p0.037). CONCLUSIONS: Co-morbid dyskinesia, dementia, or depression were
observed to be the major contributors to the fiscal burden of PD in Germany, post-
2000. An overall increase in the (estimated) costs associated with these co-morbid-
ities was evident during the time-period evaluated. Further studies to understand
the cause of increased (estimated) costs associated with these co-morbidities in PD
are warranted.
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OBJECTIVES: Multiple sclerosis (MS) is a chronic, neurodegenerative inflammatory
disease of the central nervous system. In Spain, the prevalence rate of MS is esti-
mated to range between 53 and 58 cases per 100,000. At disease onset, relapsing-
remitting MS (RRMS) is diagnosed in approximately 60% to 85% of MS patients.
Based on the available evidence, pharmacological costs of disease modifying drugs
(DMD) represent the highest proportion of direct health care costs. In order to
ensure sustainability of the health system is crucial to analyze pharmacological
cost of DMD used in the treatment of RRMS from the perspective of the health
system. METHODS: A direct medical costs analysis model was developed to assess
pharmacological costs per patient and year of treatment with DMD. Therapeutic
alternatives assessed were: interferon (IFN) -1a intramuscular, IFN -1a subcuta-
neous 22 g, IFN -1a subcutaneous 44 g, IFN -1b subcutaneous, IFN  1-b sub-
cutaneous, glatiramer acetate, natalizumab and fingolimod. Dosages for each drug
were those described in summary product characteristics. Pharmacological costs
were obtained from database of General Council of Official Colleges of Pharmacists
(BotPlus) consulted at May 2012. Costs were expressed as ex-factory price applying
7.5% discount according to RDL 8/2010. RESULTS: Pharmacological costs per pa-
tient and year of treatment for each one of the therapeutic alternatives assessed
were: 10,050.74€ for IFN -1a im; 9,357.23€ for IFN -1a sc 22g; 14,035.64€ for IFN
-1a sc 44g; 9,761.56€ for IFN -1b sc; 9,420.38€ for glatiramer acetate; 19,683.12€
for natalizumab and 19,292.90€ for fingolimod. CONCLUSIONS: Due to actual so-
cioeconomic climate and the recent measures of pharmaceutical costs contain-
ment, when selecting the most appropriate therapeutic option additionally to ef-
ficiency criteria, the economic impact on pharmacy services should be also
considered. This analysis is particularly relevant in the case of chronic diseases
with a high socioeconomic impact, as the RRMS.
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OBJECTIVES: There is a lack of long-term prospective data to document the eco-
nomic burden (direct and indirect costs) of Alzheimer’s disease (AD), especially in
moderate AD where disease management becomes more complex. The EVOCOST
study aims to describe and analyse the health care resource use and costs associ-
ated with clinical evolution in a cohort of moderate AD patients in routine medical
practice in Spain. METHODS: The EVOCOST study is a prospective 12-month mul-
ticentre cohort study recruiting community-dwelling moderate AD patients in
Spain. Health care resources (specialist, general practitioner and nurses visits, hos-
pitalisations and emergency room visits, antidementia drugs and institutionalisa-
tion) and non-health care resources (caregiver’s time for care and supervision)
were collected retrospectively. Total costs over the entire 12-month study fol-
low-up were calculated. Costs over the 3 months preceding baseline and the end of
follow-up were compared. RESULTS: A total of 209 patients were included at base-
line, 76.1% of them were women, with a mean age of 78.4 years and a mean MMSE
of 15.2. Over the entire 12-month study follow-up, the mean monthly cost per
patient was €1016 (annual cost €12197). The major cost driver was the informal
caregiver time dedicated to patient supervision and care (€852, 84% of total cost).
Other costs were as follows: antidementia drugs (€88, 9%), hospitalisation and
emergency room visits (€31, 3%), visits (€26, 3%) and institutionalisation (€20,
2%).The mean monthly cost per patient increased significantly during the 12-
month study follow-up from €902 to €1074 (	cost19%, p0.001), mainly due to
the increase in caregiver time. CONCLUSIONS: Management of community-dwell-
ing moderate AD patients in Spain is associated with a high monthly cost ( €1000/
month). The main cost driver is by far the caregiver time which is not reimbursed
by health insurance. The EVOCOST study results illustrate the economic burden of
Alzheimer’s disease on patients’ caregivers.
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OBJECTIVES:Multiple sclerosis (MS) is a chronic autoimmune disease of the central
nervous system that results in resistant incapacitation in absence of appropriate
therapy, considerably reducing patients’ qualities of life. The average number of
patients with MS reaches 2,5 million patients in the world and about 500 000 pa-
tients in Russia. METHODS: Patients registry of the follow-up care in the Clinical
and Diagnostic Center Of Demyelinating Diseases of the Tatarstan Republic be-
came the source of data on real clinical practice of maintaining patients. RESULTS:
Total number of patients – 756; 72% of them - female, 60 % developed remitting type
of MS, average disease duration – 10.3 years, average patients age – 41. During the
cost of illness analysis of MS we estimated direct costs and indirect costs. Direct
costs included diagnostics at the out-patient (24.2 Euro per year) and in-patient
department (28.98 Euro per year), medical services and pharmacotherapy during
the residence in the in-patient department (15.7 Euro per year). Average duration of
residence in the in-patient department in the care of relapse made 15 days; costs
for the residence amounted 155.5 Euro per year. The highest priced stage of pa-
tients case management is the follow-up pharmacotherapy with disease modifying
drugs (DMD’s) that amounted about 4 849.06 Euro per year. Indirect costs included
disability grant (441.7 Euro per year), GDP waste in case of absence at the working
place (146.9 per year) and in case of forced work refusal of patients (4 182.9 Euro per
year) or their relatives (2 423,9 Euro per year) and social worker help (251.9 Euro per
year). CONCLUSIONS: Cost of illness analysis of MS showed that the highest priced
stages are DMD’s therapy and GDP waste. Total direct costs amounted 5 367.9 Euro per
year, indirect costs – 7 195.6 Euro per year. Total costs amounted 12 563,62 Euro per year.
PND22
DESCRIPTIVE ANALYSIS OF THE DIRECT COSTS OF RELAPSING-REMITTING
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Multiple sclerosis (MS) is a multifocal central nervous system disorder character-
ised by inflammatory demyelinating lesions affecting white and grey matter. MS
affects quality of life of the patients and requires costy and long term treatments.
OBJECTIVES: To determine the direct medical costs incurred in the treatment of
relapsing remitting MS patients in the Social Security Mexican Institute (IMSS).
METHODS: The data for this analysis were abstracted from the IMSS records, to be
included each patient had to have at least 1 medical claim with a diagnosis of MS
between January 1, 2008 and December 31, 2008. The patients records were used to
obtain resource utilization over the year (including prescription drugs, clinician
visits, surgical procedures, diagnostic procedures, etc), the costs were obtained
from the IMSS public lists and were actualized to 2011 costs. RESULTS: A total of
172 patients were identified with a MS code, 52.33% (n90) of them met the criteria
for relapsing remitting MS. There were 54 female patients, with a female:male ratio
of 1.5:1, with a mean evolution time of 7.21 years. The total average annual cost for
each patient was MxP $173.970,64, 81.31% of which was attributable to the cost of
prescription drugs, (80.5% was associated to the cost of disease-modifying drugs in
particular (including interferon beta 1b, interferon beta 1a and glatiramer acetate);
16.2% to outpatient care (diagnostic and treatment-related procedures, office visit
charges for usual care), 1.3% to inpatient care (diagnostic or treatment-related
procedures, room and board charges, clinician inpatient visit and surgical proce-
dures) and 1.16% to emergency room care (associated to disease exacerbation
mainly). CONCLUSIONS: This analysis shows that prescription drug accounted for
81.31% of total relapsing-remitting MS related medical direct costs in the Mexican
setting and that this costs are mainly associated with the use of disease-modifying
drugs.
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OBJECTIVES: To describe economic burden for persons with SB in Germany.
METHODS: Survey data were used to capture use of health care and assistive
technologies for both last year and ten years prior to data collection. Participants
were recruited from the tertiary clinic database or when initiating care in the clinic.
Participants had to have a verifiable SB diagnosis, and a cognitive ability to respond
to the questionnaire or a caregiver able to answer questions. Data were double-
entered with queries issued to patients to improve data quality. Descriptive anal-
yses were used to summarize data. RESULTS: Information on resource use for 88
participants was collected (44% female, mean age 28.7, SD13.5). In the year prior
to data collection, 88.6% (N78) had at least one visit to a general practitioner (GP),
77.3% (N68) a visit to urologist, and 69.3% (N61) a visit to physiotherapist. Mean
number of annual visits was 7.6 GP, 3.6 urologist, and 65.3 physiotherapist visits.
Participants reporting secondary care use were found to visit hospital most often
(N38, 43.2%), followed by emergency room care (N12, 13.6%). Among responders
being hospitalized, average annual length of stay in a regular ward was 14.8 days
per person, with average hospitalization of 7.3 days. During previous ten years,
majority of responders required a wheelchair (N59, 67.0%), glasses (N57, 64.7%),
and orthopaedic shoes (N52, 59.1%), with an average of 2.5, 2.8, and 6.1 new items
respectively. CONCLUSIONS: Results indicate that persons with SB require a sub-
stantial amount of health care both in short and long term and that the overall
burden experienced by persons with SB may be high, especially if coupled by pos-
sible quality of life implications. Successful prevention, using education and tar-
geted intervention for women of childbearing age could reduce the burden, but
further research is required to fully understand economic impact of SB.
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